Toxicodynamic modeling of highly toxic organophosphorus compounds

D M Maxwell1, K M Brecht, F-C T Chang

  • 1United States Army Medical Research Institute of Chemical Defense, Research Division, Aberdeen Proving Ground, MD 21010-5400, USA. donald.maxwell@us.army.mil

Insights

Organophosphorus compounds

Area of Science:

  • Toxicology
  • Neuroscience
  • Pharmacology

Background:

  • Organophosphorus (OP) compounds are known to inhibit acetylcholine-esterase (AChE) in vitro.
  • The primary mechanism of acute in vivo OP toxicity, specifically AChE inhibition, remains debated.
  • Alternative hypotheses suggest direct toxic effects independent of AChE inhibition.

Purpose of the Study:

  • To investigate the hypothesis that AChE inhibition is the primary mechanism of acute OP toxicity.
  • To mathematically model the in vivo lethal effects of highly toxic OP compounds.
  • To quantify the variation in OP toxicity attributable to AChE inhibition.

Main Methods:

  • Mathematical modeling of in vivo lethal effects.
  • Analysis of OP compound toxicity data.
  • Statistical determination of AChE inhibition's contribution to toxicity.

Main Results:

  • The study quantifies the relationship between AChE inhibition and OP compound lethality.
  • Mathematical models are used to assess the extent to which AChE inhibition explains OP toxicity.
  • Results provide insights into the dose-response relationship of OP compounds.

Conclusions:

  • The findings contribute to understanding the mechanism of acute organophosphorus toxicity.
  • The study evaluates the central role of AChE inhibition in OP-induced lethality.
  • This research informs risk assessment and the development of effective treatments for OP poisoning.

Related Concept Videos

Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...